Tags

Type your tag names separated by a space and hit enter

Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea.
Surgery. 2014 Apr; 155(4):689-95.S

Abstract

BACKGROUND

We examined the frequency of the BRAF(V600E) mutation and compared the clinicopathologic features based on the BRAF(V600E) mutation status in multifocal papillary thyroid carcinoma (PTC).

METHODS

A total 85 patients who were diagnosed with multifocal PTC were enrolled. We confirmed the status of the BRAF(V600E) mutation in each tumor focus by the real-time polymerase chain reaction technique.

RESULTS

Among the 85 patients, 49 (57.6%), 34 (40.0%), and 2 (2.4%) patients were determined to have all BRAF(V600E)-positive, mixed BRAF(V600E), and all BRAF(V600E)-negative in their tumor foci, respectively. When we compared clinicopathologic features according to the BRAF(V600E) mutation status of the dominant tumor, the BRAF(V600E) -positive group (n = 70) showed more extrathyroidal invasion in the dominant tumor (32.9% vs 6.7%, P = .041) and more lymph node metastasis (67.2% vs 40.0%, P = .049) than the BRAF(V600E) -negative group (n = 15). Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .039), showed increased extrathyroidal invasion (38.8% vs 14.7%, P = .017) and lymph node metastasis (71.4% vs 48.4%, P = .038), and received more radioactive iodine therapy (79.2% vs 52.9%, P = .012) than the mixed BRAF(V600E) mutation group. A larger tumor size and heavier preoperative body weight was positively correlated with the relative expression of BRAF(V600E) mutation calculated by 2(-△△Ct) method.

CONCLUSION

Most of the Korean patients with multifocal PTC had the BRAF(V600E) mutation in one or more tumor foci, and all BRAF(V600E)-positive multifocal PTC showed more aggressive features.

Authors+Show Affiliations

Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Nuclear Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Pathology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Surgery, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea. Electronic address: bycho@cau.ac.kr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24612623

Citation

Ahn, Hwa Young, et al. "Clinical Significance of the BRAF V600E Mutation in Multifocal Papillary Thyroid Carcinoma in Korea." Surgery, vol. 155, no. 4, 2014, pp. 689-95.
Ahn HY, Chung YJ, Kim BS, et al. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. Surgery. 2014;155(4):689-95.
Ahn, H. Y., Chung, Y. J., Kim, B. S., Kang, K. H., Seok, J. W., Kim, H. S., Park, S. J., & Cho, B. Y. (2014). Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. Surgery, 155(4), 689-95. https://doi.org/10.1016/j.surg.2013.12.025
Ahn HY, et al. Clinical Significance of the BRAF V600E Mutation in Multifocal Papillary Thyroid Carcinoma in Korea. Surgery. 2014;155(4):689-95. PubMed PMID: 24612623.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. AU - Ahn,Hwa Young, AU - Chung,Yun Jae, AU - Kim,Byung Seup, AU - Kang,Kyung Ho, AU - Seok,Ju Won, AU - Kim,Hee Sung, AU - Park,Sung Jun, AU - Cho,Bo Youn, Y1 - 2013/12/27/ PY - 2013/09/25/received PY - 2013/12/19/accepted PY - 2014/3/12/entrez PY - 2014/3/13/pubmed PY - 2014/5/27/medline SP - 689 EP - 95 JF - Surgery JO - Surgery VL - 155 IS - 4 N2 - BACKGROUND: We examined the frequency of the BRAF(V600E) mutation and compared the clinicopathologic features based on the BRAF(V600E) mutation status in multifocal papillary thyroid carcinoma (PTC). METHODS: A total 85 patients who were diagnosed with multifocal PTC were enrolled. We confirmed the status of the BRAF(V600E) mutation in each tumor focus by the real-time polymerase chain reaction technique. RESULTS: Among the 85 patients, 49 (57.6%), 34 (40.0%), and 2 (2.4%) patients were determined to have all BRAF(V600E)-positive, mixed BRAF(V600E), and all BRAF(V600E)-negative in their tumor foci, respectively. When we compared clinicopathologic features according to the BRAF(V600E) mutation status of the dominant tumor, the BRAF(V600E) -positive group (n = 70) showed more extrathyroidal invasion in the dominant tumor (32.9% vs 6.7%, P = .041) and more lymph node metastasis (67.2% vs 40.0%, P = .049) than the BRAF(V600E) -negative group (n = 15). Considering all tumor foci, the all BRAF(V600E) mutation group exhibited a younger population (P = .039), showed increased extrathyroidal invasion (38.8% vs 14.7%, P = .017) and lymph node metastasis (71.4% vs 48.4%, P = .038), and received more radioactive iodine therapy (79.2% vs 52.9%, P = .012) than the mixed BRAF(V600E) mutation group. A larger tumor size and heavier preoperative body weight was positively correlated with the relative expression of BRAF(V600E) mutation calculated by 2(-△△Ct) method. CONCLUSION: Most of the Korean patients with multifocal PTC had the BRAF(V600E) mutation in one or more tumor foci, and all BRAF(V600E)-positive multifocal PTC showed more aggressive features. SN - 1532-7361 UR - https://www.unboundmedicine.com/medline/citation/24612623/Clinical_significance_of_the_BRAF_V600E_mutation_in_multifocal_papillary_thyroid_carcinoma_in_Korea_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039-6060(13)00644-2 DB - PRIME DP - Unbound Medicine ER -